UCB (OTCMKTS:UCBJY) Trading Down 4.5% – Here’s Why

UCB SA (OTCMKTS:UCBJY) traded down 4.5% during trading on Friday . The company traded as low as $122.36 and last traded at $122.76. Approximately 8,405 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 37,645 shares. The stock had previously closed at $128.5750.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on UCBJY shares. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 4th. Finally, Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

UCB Stock Down 4.9%

The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20. The business has a fifty day moving average price of $134.39 and a 200 day moving average price of $142.95.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.